Scholarlink

<p>Hepatitis B virus (HBV) remains a global health burden, with current therapies rarely achieving functional cure, highlighting an unmet need for novel strategies. Here, we isolate a high-affinity nanobody, VHH4917, against the viral surface antigen (HBsAg) from an alpaca nanobodies phage library. VHH4917 exhibits a multi-phenotypic antiviral profile that extends beyond mere neutralization. It not only accelerates HBsAg clearance in vivo but also potently suppresses HBV replication, transcription, and particle secretion through distinct mechanisms. Further engineering by site-specific PEGylation markedly prolongs its circulating half-life and enhances in vivo antiviral efficacy in mouse models of chronic HBV infection. Our work characterizes VHH4917 as a potent, novel therapeutic candidate and provides a promising protein-engineering framework for advancing nanobody-based immunotherapy against chronic hepatitis B.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A PEGylated nanobody against HBsAg exhibits pleiotropic antiviral efficacy in hepatitis B models

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Qun Yang,
  • Wenhua Liu,
  • Meiling Huang,
  • Mingyi Lin,
  • Jieli Hu,
  • Jie Wei,
  • Qian Yang,
  • Sisi Wang,
  • Deqiang Wang,
  • Ailong Huang,
  • Xuefei Cai

摘要

Hepatitis B virus (HBV) remains a global health burden, with current therapies rarely achieving functional cure, highlighting an unmet need for novel strategies. Here, we isolate a high-affinity nanobody, VHH4917, against the viral surface antigen (HBsAg) from an alpaca nanobodies phage library. VHH4917 exhibits a multi-phenotypic antiviral profile that extends beyond mere neutralization. It not only accelerates HBsAg clearance in vivo but also potently suppresses HBV replication, transcription, and particle secretion through distinct mechanisms. Further engineering by site-specific PEGylation markedly prolongs its circulating half-life and enhances in vivo antiviral efficacy in mouse models of chronic HBV infection. Our work characterizes VHH4917 as a potent, novel therapeutic candidate and provides a promising protein-engineering framework for advancing nanobody-based immunotherapy against chronic hepatitis B.

Graphical abstract